Mirum Pharmaceuticals, Inc. (MIRM) experienced a pre-market plunge of 5.17% on Thursday.

The movement follows a series of analyst price target adjustments for the healthcare company. Several firms, including Stifel, Raymond James, and Morgan Stanley, raised their price targets on Mirum Pharmaceuticals. However, RBC lowered its target slightly to $128 from $130 while keeping an Outperform rating.

According to FactSet data, the stock maintains an average buy rating with a mean price target of $122.36. The mixed analyst sentiment, particularly the downward adjustment from RBC, appears to have contributed to the pre-market decline.